Literature DB >> 12620229

Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing.

Masataka Sugimoto1, Mei-Ling Kuo, Martine F Roussel, Charles J Sherr.   

Abstract

The p19(Arf) tumor suppressor, a nucleolar protein, binds to Mdm2 to induce p53-dependent cell cycle arrest. Arf also prevents the proliferation of cells lacking Mdm2 and p53, albeit less efficiently. We show that p19(Arf) inhibits production of ribosomal RNA, retarding processing of 47/45S and 32S precursors. These effects correlate with but do not strictly depend upon inhibition of rRNA biosynthesis or cell cycle arrest, are not mimicked by p53, and require neither p53 nor Mdm2. Arf mutants lacking conserved amino acid residues 2-14 do not block rRNA synthesis and processing or inhibit cell proliferation. Evolution may have linked a primordial nucleolar Arf function to Mdm2 and p53, creating a more efficient checkpoint-signaling pathway for coordinating ribosomal biogenesis and cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620229     DOI: 10.1016/s1097-2765(03)00057-1

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  106 in total

1.  RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis.

Authors:  Anthony J Saporita; Hsiang-Chun Chang; Crystal L Winkeler; Anthony J Apicelli; Raleigh D Kladney; Jianbo Wang; R Reid Townsend; Loren S Michel; Jason D Weber
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

2.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

3.  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Tomasz B Owczarek; Takashi Kobayashi; Ricardo Ramirez; Lijie Rong; Anna M Puzio-Kuter; Gopa Iyer; Min Yuen Teo; Francisco Sánchez-Vega; Jingqiang Wang; Nikolaus Schultz; Tian Zheng; David B Solit; Hikmat A Al-Ahmadie; Cory Abate-Shen
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

4.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

5.  ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Authors:  Suzanne N Brady; Yue Yu; Leonard B Maggi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

6.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Authors:  Nabeel Bardeesy; Andrew J Aguirre; Gerald C Chu; Kuang-Hung Cheng; Lyle V Lopez; Aram F Hezel; Bin Feng; Cameron Brennan; Ralph Weissleder; Umar Mahmood; Douglas Hanahan; Mark S Redston; Lynda Chin; Ronald A Depinho
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

7.  5-fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs.

Authors:  Feng Fang; Jason Hoskins; J Scott Butler
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

8.  A targeting modality for destruction of RNA polymerase I that possesses anticancer activity.

Authors:  Karita Peltonen; Laureen Colis; Hester Liu; Rishi Trivedi; Michael S Moubarek; Henna M Moore; Baoyan Bai; Michelle A Rudek; Charles J Bieberich; Marikki Laiho
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

Review 9.  Probing the mechanisms underlying human diseases in making ribosomes.

Authors:  Katherine I Farley; Susan J Baserga
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

10.  Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study.

Authors:  Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Lebriz Altay; Bjorn Bakker; Bobby P C Koeleman; Lambertus A Kiemeney; Dorine W Swinkels; Jan E E Keunen; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.